MedTrace Logo

Clinical Study on the Efficacy of Natural Stem Cell Mobilizers on Parkinson Disease

NCT05699694 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-05-29

No results posted yet for this study

Summary

Parkinson's disease is defined as the progressive loss or deterioration of dopaminergic neurons, Treatment approaches to maintain the normal dopamine level that include medication, surgery, cell therapy supplementation of L-Dihydroxyphenylalanine (L-Dopa), a precursor of dopamina, Stem cells from bone marrow can be mobilized according to the need of repair of the tissue. Suggested use of the food supplement actually sold in the USA and in Europe: Take two capsules, 1 to 3 times per day with a glass of water. Increase the Stem Cell circulating in the peripheral blood.

Conditions

  • Parkinson Disease

Interventions

DIETARY_SUPPLEMENT

StemRegen product

Products will be consumed orally in capsules with a glass of water. Six capsules per day will be consumed daily for 6 month. Two main administration schedules are possible: Two in the morning, 2 at noon, and 2 in the evening at each meal depending on individual habits of the volunteers to reduce non-compliance.

Sponsors & Collaborators

  • Sociedad Española de Medicina Regenerativa y Terapia Celular

    lead OTHER

Principal Investigators

  • Miguel G Garber, MD · Healthy Longevity Clinic

  • Felix Pedrero Ramallo, MD · Clinica Castello 68

  • Christian Drapeou, PhD · Kalyagen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-05
Primary Completion
2025-02-01
Completion
2025-10-15

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05699694 on ClinicalTrials.gov